TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04010266
Drug: multi-modality pain management
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
Study: NCT05111366
Drug: TQB2450 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
Study: NCT05182047
Drug: Sinecod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinecod syrup will be administered orally.
Study: NCT06468709
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
Study: NCT04060407
Drug: CD24Fc
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
Study: NCT04262895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06228430
Drug: Zovirax™ 800 mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zovirax™ 800 mg Tablet (Reference Drug)
Study: NCT05850936
Drug: Assigned Interventions: IOP-lowering eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the first choice for treatment.~1. If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added; If the IOP reduction of 10% is then not achieved at 1 month after adding Brinzolamide 1%, Alphagan 0.2% or Alphagan-P 0.15% eye drops will be added.~2. If an individual is allergic to Xalacom or feels uncomfortable, the eye drops will be switched to Azarga eye drops (combination drops, fixed Brinzolamide with Timolol); If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added.~3. The effect of IOP lowering would be assessed every week after applying each medication until the target IOP was achieved and follow up the schedule time. If an IOP reduction of 10% is then not achieved, the individual will be excluded from the study.
Study: NCT05148481
Drug: BIIB104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05148481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05306132
Drug: ASKC202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Forms: Tablets; Administration: Oral administration
Study: NCT06207539
Drug: hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company
Normalized name: n-butyl acrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
Study: NCT05724849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm/group description.
Study: NCT05442515
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
Study: NCT06267963
Drug: Oral [14C]PF-07220060
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of \[14C\]PF-07220060, will be administered as a liquid formulation in Cohort 1.
Study: NCT04753164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
Study: NCT06267963
Drug: IV [14C] PF-07220060
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single IV infusion of \[14C\]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.
Study: NCT06476223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
Study: NCT05510323
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RAS blockade as much as tolerated or allowed
Study: NCT05510323
Drug: Prednisolone plus Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS blockade as much as tolerated or allowed
Study: NCT05826964
Drug: AI+CDK4/6i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib
Study: NCT05826964
Drug: SERD+CDK4/6i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib
Study: NCT05826964
Drug: mTOR inhibitor + AI
Normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study: NCT05826964
Drug: mTOR inhibitor + SERD
Normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study: NCT05826964
Drug: mTOR inhibitor + Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study: NCT05826964
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
Study: NCT05826964
Drug: Oral SERD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study: NCT06226727
Drug: BR1019
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06226727
Drug: BR1019-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06226727
Drug: BR1019-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT05935579
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
Study: NCT05804383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT06264388
Drug: DB107-RRV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.
Study: NCT06264388
Drug: DB107-FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
Study: NCT05874180
Drug: DW6013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition
Study: NCT03594162
Drug: iC9-CAR19 cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of two dose levels will be given: 1 x 10\^5 or 5 x 10\^5
Study: NCT03594162
Drug: AP1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
Study: NCT03594162
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
Study: NCT00605774
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
Study: NCT00605774
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
Study: NCT05409235
Drug: OTT166
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive OTT166 ophthalmic solution
Study: NCT05861791
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
Study: NCT05861791
Drug: ketorolac tromethamine with nefopam hydrochloride
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
Study: NCT04935021
Drug: ATTR-CM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment
Study: NCT04709575
Drug: REGN5714
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT04709575
Drug: REGN5715
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT04709575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that replaces REGN5713-5714-5715
Study: NCT05953740
Drug: MK-5720
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection
Study: NCT05953740
Drug: Placebo to MK-5720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IM Injection matched to MK-5720
Study: NCT06152172
Drug: KYV-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
Study: NCT01395940
Drug: KLH-2109
Normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06152172
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
Study: NCT05782881
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment and management according to the guidelines
Study: NCT05324410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-840 for oral administration.
Study: NCT05409027
Drug: SPI-62
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI-62 is supplied as 1 mg tablets for oral dosing.
Study: NCT05112692
Drug: Estradiol Valerate and progesterone
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
Study: NCT05001243
Drug: Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBOHB to improve uncorrected near vision in healthy presbyopic patients
Study: NCT06371222
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: controlled group
Study: NCT05903131
Drug: Progestin
Normalized name: Progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Released via the levonorgestrel-releasing IUD.
Study: NCT05755191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Doses
Study: NCT05041790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
Study: NCT04904185
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
Study: NCT05225961
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
Study: NCT00006412
Drug: Pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06259331
Drug: SPN-812 (600mg, QD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER
Study: NCT04817228
Drug: EscharEx (EX-02 formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
Study: NCT00002188
Drug: Alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06484608
Drug: Isotonic Saline with Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
Study: NCT06497049
Drug: GP40221
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for Subcutaneous Administration 1.34 mg/ml
Study: NCT04847674
Drug: TEV-53275 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous (sc) injection
Study: NCT04847674
Drug: TEV-53275 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous (sc) injection
Study: NCT04847674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching subcutaneous (sc) placebo injection
Study: NCT06091332
Drug: Starch flake
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
Study: NCT05233566
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fluid acting as a placebo
Study: NCT06416865
Drug: AJU-C52L, AJU-C52
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks.
Study: NCT06416865
Drug: C52R1L, C52R1M
Approvals — FDA: no, EMA: no, PMDA: no
Description: C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks.
Study: NCT04952194
Drug: Carbidopa and Levodopa Controlled Release Tablets
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
Study: NCT06014073
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Study: NCT06277804
Drug: LTC004 in Combination With Cyclophosphamide and Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
Study: NCT05459493
Drug: TJAOA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once enrolled, participants will be administrated TJAOA101
Study: NCT04999631
Drug: Ethanol Solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control
Study: NCT05956769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection
Study: NCT05583188
Drug: Standard of care neoadjuvant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
Study: NCT05178849
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
Study: NCT06258148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, SC, once a week
Study: NCT05054530
Drug: GMA106 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
Study: NCT05054530
Drug: GMA106 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for GMA106
Study: NCT06188442
Drug: DoxyODPrEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
Study: NCT06188442
Drug: DoxyPEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
Study: NCT00755066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal spray
Study: NCT04685876
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (normal saline).
Study: NCT05340153
Drug: Artemether-Lumefantrine Drug Combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
Study: NCT05112666
Drug: other DOACs
Normalized name: Doans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
Study: NCT05112666
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
Study: NCT04285320
Drug: Intravesical antibiotic instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~* Amikacin-30 mg in 60 ml of sterile water~* Gentamycin-80mg in 60ml sterile water~* Tobramycin-80 mg in 100 ml of sterile water
Study: NCT04935476
Drug: Placebo 85 mg PO BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet, twice daily for 21 days.